Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AfterDmab
NL-OMON43199Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of zoledronic acid and denosumab in osteoporosis (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Lumbar spine and hip bone mineral density at 24 months. Started Oct 2016; status: active, not recruiting.
02
Drugs
zoledronic aciddenosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NL-OMON43199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43199.